Yazar "Gedük, Ayfer" seçeneğine göre listele
Listeleniyor 1 - 4 / 4
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Correction to: Efects of AGEs, sRAGE and HMGB1 on clinical outcomes in multiple myeloma(Springer India, 2023) Gedük, Ayfer; Öztaş, Berrin; Eryılmaz, Baldan Huri; Demirsoy, Esra Terzi; Mengüç, Meral Uluköylü; Ünal, SerkanCorrection to: Efects of AGEs, sRAGE and HMGB1 on Clinical Outcomes in Multiple MyelomaÖğe Effects of AGEs, sRAGE and HMGB1 on clinical outcomes in multiple myeloma(Springer India, 2023) Gedük, Ayfer; Öztaş, Berrin; Eryılmaz, Baldan Huri; Demirsoy, Esra Terzi; Mengüç, Meral Uluköylü; Ünal, SerkanPurpose The receptor for advanced glycation end products (RAGE) upregulated during the onset and progression of cancer and bone-related pathologies. In this study, we aimed to investigate the role of serum advanced glycation end products (AGEs), soluble RAGE (sRAGE) and high mobility group box 1 (HMGB1), in multiple myeloma (MM). Methods AGEs, sRAGE and HMGB1 concentrations of 54 newly diagnosed MM patients and 30 healthy volunteers were measured by ELISA. The estimations were done only once at diagnosis. The medical records of the patients were evaluated. Results There was no significant difference between the AGEs and sRAGE levels between the patient and control groups (p = 0.273, p = 0.313). In ROC analysis, a HMGB1 cutoff value of > 9170 pg/ml accurately discriminated MM patients (AUC = 0.672, 95% CI 0.561-0.77, p = 0.0034). AGEs level was found to be significantly higher in early-stage disease and HMGB1 in advanced disease (p = 0.022, p = 0.026). High HMGB1 levels were detected in patients whose with better first-line treatment response (p = 0.019). At 36 months, 54% of patients with low AGE were alive, compared to 79% of patients with high AGE (p = 0.055). Patients with high HMGB1 levels tended to have a longer PFS (median 43 mo [95% CI; 20.68-65.31] ) compared to patients with low HMGB1 levels (median 25 mo [95% CI; 12.39-37.6], p = 0.054). Conclusion In this study, a significant elevation of serum HMGB1 level was found in MM patients. In addition, the positive effects of RAGE ligands on treatment response and prognosis were determined.Öğe Programmed cell death ligand 1 expression level and prognostic significance in acute myeloid leukemia(Springer India, 2022) Gedük, Ayfer; Ateşoğlu, Elif Birtaş; Mehtap, Özgür; Demirsoy, Esra Terzi; Mengüç, Meral Uluköylü; Tarkun, PınarPurpose: We aimed to evaluate the expression level of programmed death ligand-1 (PD-L1) and its effects on prognosis in acute myeloid leukemia. Methods: The flow cytometry was used to detect PD-L1 expression on leukemic cells of 86 de novo acute myeloid leukemia patients with longitudinal follow-up. Results: Median follow-up was 13 (0-73) months. The mean of expression level was 3.22 +/- 0.47 at diagnosis and ranged from 0 to 28%. PD-L1 expression tended to be lower in patients with acute promyelocytic leukemia (2.47 +/- 1.08, p = 0.09) but there was no significant difference between neither diagnostic nor cytogenetic subgroups. There was no difference in PD-L1 levels between the patients who achieved complete remission (3.4 +/- 0.61) and those who did not (2.91 +/- 0.72, p = 0.94). The patients with low PD-L1 at diagnosis (median 25 mo [95% CI; 0-56.7]) had a longer overall survival compared with high PD-L1 (median 13 mo [95% CI; 5.52-25.17], p = 0.079). PD-L1 expression was lower at relapse (2.04 +/- 0.79) compared to initial diagnosis (4.52 +/- 0.93, p = 0.049). The patients who had overall survival longer than 1 year showed lower PD-L1 expression at relapse (0.66 +/- 0.93) compared with who had not (5.06 +/- 4.28, p = 0.052). A negative correlation between CD33 and PD-L1 (r = - 0.303, p = 0.005) was detected. Conclusion: Despite its low expression levels, PD-L1 appears to be a clinically important prognostic factor. The negative correlation determined between PD-L1 and CD33 supports the combination approach of PD-L1 inhibitors and CD33 targeted immunotherapies.Öğe The role of interim PET/CT on survival in diffuse large B cell lymphoma(CIG Media Group LP, 2021) Mengüç, Meral Uluköylü; Mehtap, Özgür; Görür, Gözde Dağlıöz; Ateşoglu, Elif Birtaş; Gedük, Ayfer; Ünal, SerkanDiffuse large B cell lymphoma is an aggressive lymphoma which fails to cure in first line almost in one third of patients. Earlier risk assessment and tailoring therapy with interim PET will select a group of patients having high risk to relapse. Although interim PET guided therapy has been established in Hodgkin Lymphoma; the role of interim PET in non-Hodgkin lymphomas is debated. In this study we searched the association of interim PET on survival in 103 DLBCL patients.Interim PET assessed by 5-point Deauville Score predicts PFS and OS with a PPV of 65.4% and a NPV of 77.9%. Background: Diffuse large B cell lymphoma is the most frequent aggressive non-Hodgkin lymphoma. Predicting response and estimating prognosis earlier makes management of this heterogeneous lymphoma more satisfying. Interim PET response is established in Hodgkin Lymphoma to tailor the therapy but results for non-Hodgkin Lymphoma is unconvincing. In the current study evaluation of interim PET and survival outcomes of 103 DLBCL patients is performed. Patients and Methods: About 103 Patients with DLBCL followed up in a single center between 2009 and 2019 were enrolled the study. All patients received R-CHOP chemoimmunotherapy at first line. Interim PET was performed after at least one or more cycles. All PET scans were performed with 18 F-FDG isotope as PET/CT. PET scoring results were evaluated according to the 5-Point Deauville Scoring system defined in the National Comprehensive Cancer Network clinical guidelines for iPET and eotPET. 5-P DS of scores of 1 to 3 were defined as negative scans, and scores of 4 to 5 were considered to be positive scans. Results: Forty-six (44.7%) Female and 57 (55.3%) male aged between 25 and 83 (median 57) years newly diagnosed DLBCL patients were enrolled in the study. Median PFS was 21 (interquartile range 8.5-53.7) months and median OS was 33.5 (interquartile range 12.5-62.9) months for the total cohort. Positive predictive value of interim PET according to Deauville scoring system was 65.4% and negative predictive value was 77.9%. Conclusion: Our study showed that according to Deauville 5 point scale (D 5PS) scoring system, interim PET-positive patients have shorter both PFS and OS than iPET-negative patients. (C) 2021 Elsevier Inc. All rights reserved.
